Clinical Trials Directory

Trials / Completed

CompletedNCT01456572

Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
65 (actual)
Sponsor
University Hospital, Basel, Switzerland · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the reciprocal control between gastric functions and intestinal parameters in the development of satiation in obese people.

Detailed description

Obesity has reached pandemic proportions, obesity-associated complications are extensive and the current treatment options are limited. These facts demonstrate the need for an improved understanding of the pathogenesis of obesity. The gastrointestinal tract plays a key element in the control of satiation; discrepancies exist, however, for the role of gastric and intestinal parameters in the control of satiation in relation to body mass. To achieve a comprehensive understanding for the reciprocal control between gastric functions and intestinal parameters in the development of satiation in obese people the investigators will compare satiation parameters, gastric emptying and plasma glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY) and ghrelin levels between normal and obese healthy volunteers. Time needed to reach the level of satiation and total calorie intake will be measured by a standardized nutrient drink test; gastric emptying of solids by a 13C-octanoic acid breath test; and plasma GLP-1, PYY and ghrelin levels will be measured after a standardized nutrient drink.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTensure plus17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
DIETARY_SUPPLEMENTstandardized test mealscrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid

Timeline

Start date
2007-01-01
Primary completion
2011-02-01
Completion
2011-07-01
First posted
2011-10-20
Last updated
2011-10-20

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01456572. Inclusion in this directory is not an endorsement.